A biotech hedge fund births a new immunology company - STAT
Source:STAT
Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.
Related Articles
OpenAI CEO Sam Altman announces 'major' price cuts as the company signals a focus on cost efficiency - Business Insider
OpenAI announced it would cost less to use two of its latest AI models.
America's housing market could run out of something more important than homes - Fox News
A new report challenges the housing shortage narrative, arguing slower population growth and reduced …
Exclusive: FDA narrows in on search for new biologics and vaccines leader - Endpoints News
The FDA is getting closer to announcing a director of the Center for Biologics Evaluation and …
Live Q&A: What’s Next for Global Markets After Japan’s Bond Shock and Trump’s Greenland Move - Bloomberg
Bloomberg reporters take your questions after a bond rout and Trump’s foreign policy whiplash sends …